ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal

被引：41

作者：

Lounis, Nacer ^{[1
]}

Gevers, Tom ^{[1
]}

Van den Berg, Joke ^{[1
]}

Vranckx, Luc ^{[1
]}

Andries, Koen ^{[1
]}

机构：

[1] Johnson & Johnson, Tibotec BVBA, Dept Antimicrobial Res, B-2340 Beerse, Belgium

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2009年 / 53卷 / 11期

关键词：

BEIGE MOUSE MODEL; LUNG-DISEASE; COMPLEX; CLARITHROMYCIN; MICE; TUBERCULOSIS; COMBINATION; INFECTIONS; MANAGEMENT; ETHAMBUTOL;

D O I：

10.1128/AAC.00689-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学];

摘要：

The efficacy of ATP synthase inhibitor TMC207 was assessed in early and late Mycobacterium avium infections in mice. In contrast to what was earlier observed for M. tuberculosis, a bacteriostatic effect was obtained. In vitro, the minimal bactericidal concentration (MBC)/MIC ratio was very high. The MBC was more relevant for assessment of pharmacokinetic/pharmacodynamic relationships than the MIC.

引用

页码：4927 / 4929

页数：3

共 16 条

[1]

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[2]

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome [J].

Benson, CA ;

Williams, PL ;

Currier, JS ;

Holland, F ;

Mahon, LF ;

MacGregor, RR ;

Inderlied, CB ;

Flexner, C ;

Neidig, J ;

Chaisson, R ;

Notario, GF ;

Hafner, R .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1234-1243

[3]

DIACON AH, N ENGL J MED, V360, P2397

[4]

INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].

FERNANDES, PB ;

HARDY, DJ ;

MCDANIEL, D ;

HANSON, CW ;

SWANSON, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534

[5]

INVIVO ACTIVITY OF AMIKACIN ALONE OR IN COMBINATION WITH CLOFAZIMINE OR RIFABUTIN OR BOTH AGAINST ACUTE EXPERIMENTAL MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN BEIGE MICE [J].

GANGADHARAM, PRJ ;

PERUMAL, VK ;

PODAPATI, NR ;

KESAVALU, L ;

ISEMAN, MD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1400-1403

[6]

Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease [J].

Griffith, DE ;

Brown-Elliott, BA ;

Shepherd, S ;

McLarty, J ;

Griffith, L ;

Wallace, RJ .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (02) :250-253

[7]

Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease -: Diagnostic and management limitations [J].

Huang, JH ;

Kao, PN ;

Adi, V ;

Ruoss, SJ .

CHEST, 1999, 115 (04) :1033-1040

[8]

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor [J].

Huitric, Emma ;

Verhasselt, Peter ;

Andries, Koen ;

Hoffner, Sven E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4202-4204

[9]

AMIKACIN, CIPROFLOXACIN, AND IMIPENEM TREATMENT FOR DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION OF BEIGE MICE [J].

INDERLIED, CB ;

KOLONOSKI, PT ;

WU, M ;

YOUNG, LS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :176-180

[10]

Medical management of pulmonary disease caused by Mycobacterium avium complex [J].

Iseman, MD .

CLINICS IN CHEST MEDICINE, 2002, 23 (03) :633-+

← 1 2 →